ProtoReady / ICH M11 checklist
ICH M11 checklist: what your protocol template must contain
The final ICH M11 template fixes the headings, their order and a set of structured fields. This checklist lists all of them, with where each section usually sits in the TransCelerate Common Protocol Template.
What ICH M11 changes
ICH M11, the Clinical electronic Structured Harmonised Protocol (CeSHarP), is a guideline, a protocol template and a technical specification. ICH adopted it on 19 November 2025. The FDA published its final guidance on 21 May 2026, and the EMA guideline came into effect on 11 June 2026.
The template does more than suggest a layout. It defines which content is free text and which is a structured data element, so that a protocol can be exchanged between systems. In practice, most sponsor templates written before 2026 need changes to headings, the title page, the synopsis and the description of estimands.
Four rules that trip up existing templates
- Never delete a level 1 or level 2 heading. If a heading does not apply to your trial, keep it and write "Not applicable".
- Don't rename or renumber those headings. You can add a level 2 heading, but only at the end of its section.
- Headings in braces are conditional. For example, 6.7.2 {Randomisation} is included only when the trial is randomised.
- Every primary and secondary objective needs an endpoint, even when the trial does not estimate a treatment effect.
The structured fields before section 1
Title page: 21 fields
The title page is a fixed list of fields in a fixed order. It includes the full title, trial acronym, sponsor protocol identifier, version number and date, amendment identifier and scope, investigational product code and name, trial phase, short title, sponsor and co-sponsor details, regulatory and trial registry identifiers, sponsor approval and signatory, and the medical expert contact. Several are conditional, but none can be silently dropped.
Amendment details
Amended protocols carry a structured summary before the table of contents: the reasons for the amendment, its impact on participant safety and on data reliability, and an overview table of changes with the section concerned and a short rationale.
Synopsis: the overall design fields
Section 1.1.2 holds 19 structured fields, such as intervention model, population diagnosis, control type, assignment method, stratification, number of arms, blinding schema and blinded roles, planned number of participants, durations and committees. These are the fields most often missing from legacy synopses, which describe the design in prose.
Estimands in section 3
For each primary and secondary objective, M11 expects the five estimand attributes of ICH E9(R1) in a table: population, treatment, endpoint, population-level summary, and each intercurrent event with its handling strategy. A strategy left blank is easy to miss in review, and it leaves the estimand incomplete.
The 14 sections, mapped to the TransCelerate CPT
| M11 | Section and main content | Usual CPT section |
|---|---|---|
| 1 | Protocol summary Synopsis with structured overall design, trial schema, Schedule of Activities | 1 |
| 2 | Introduction Purpose of trial, benefit-risk assessment | 2 |
| 3 | Trial objectives and associated estimands Primary and secondary objectives, each with an endpoint and estimand attributes | 3 |
| 4 | Trial design Design, rationale, stopping rules, start and end of trial, access after the trial | 4 |
| 5 | Trial population Rationale, inclusion, exclusion, contraception, lifestyle, screen failures | 5 |
| 6 | Trial intervention and concomitant therapy Ten level 2 headings, from description to concomitant therapy | 6 |
| 7 | Discontinuation and withdrawal Discontinuation of intervention, withdrawal, loss to follow-up | 7 |
| 8 | Trial assessments and procedures Screening, efficacy, safety, pharmacokinetics, biomarkers, immunogenicity, health economics | 8 |
| 9 | Adverse events and special safety situations Definitions, collection and reporting, pregnancy, special situations | 8 and appendix |
| 10 | Statistical considerations Eleven level 2 headings, from analysis sets to sample size | 9 |
| 11 | Trial oversight and other general considerations Regulatory and ethical considerations, consent, committees, data governance and more | 10 (appendix) |
| 12 | Appendix: supporting details Laboratory tests, country-specific differences, prior amendments | 10 (appendices) |
| 13 | Appendix: glossary of terms and abbreviations | 10 (appendix) |
| 14 | Appendix: references | 11 |
CPT sections refer to versions released before 2026. The 2026 release of the Common Protocol Template follows the M11 structure.
How to use the checklist
- Start with your sponsor template, not a single protocol: fixing the template fixes every future protocol.
- Check the four rules first. Most legacy templates break at least two of them.
- Then go through the title page, the overall design fields and the estimand table, which are where structured data is lost.
- Finish with the level 2 headings, section by section, using the CPT column to find where your content currently lives.
Once the template is right, the same structure lets you produce a CDISC USDM file from each protocol. USDM covers all M11 data elements, so a well-structured M11 protocol is most of the way to a machine-readable study definition.
Get the checklist as a PDF, with a worked example
Two pages you can tick through, plus the CDISC pilot study LZZT restated in M11 format with its gap report, USDM v4 file and Schedule of Activities.